Results 121 to 130 of about 133,537 (299)

Duration of adjuvant chemotherapy for stage III colon cancer [PDF]

, 2018
BACKGROUND Since 2004, a regimen of 6 months of treatment with oxaliplatin plus a fluoropyrimidine has been standard adjuvant therapy in patients with stage III colon cancer.
Andre, Thierry, Boukovinas, Ioannis, Grothey, Axel, Iveson, Timothy, Kerr, Rachel, Labianca, Roberto, Meyerhardt, Jeffrey A., Meyers, Jeffrey P., Niedzwiecki, Donna, Paul, James, Renfro, Lindsay A., Sargent, Daniel J., Saunders, Mark, Shi, Qian, Shields, Anthony F., Sobrero, Alberto F., Souglakos, John, Taieb, Julien, Torri, Valter, Vernerey, Dewi, Watanabe, Toshiaki, Yamanaka, Takeharu, Yoshino, Takayuki   +22 more
core   +1 more source

Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD.

Journal of Clinical Oncology, 2020
PURPOSE The PETACC 6 trial investigates whether the addition of oxaliplatin to preoperative capecitabine-based chemoradiation and postoperative capecitabine improves disease-free survival (DFS) in locally advanced rectal cancer.
H. Schmoll, A. Stein, E. Van Cutsem, T. Price, R. Hofheinz, B. Nordlinger, J. Daisne, J. Janssens, B. Brenner, H. Reinel, S. Hollerbach, K. Caca, F. Fauth, C. Hannig, J. Zalcberg, N. Tebbutt, M. Mauer, S. Marréaud, M. Lutz, K. Haustermans   +19 more
semanticscholar   +1 more source

Patient‐Derived 3D‐Bioprinted Intrahepatic Cholangiocarcinoma Models Recapitulate Tumor Autologous Traits and Predict Personalized Adjuvant Therapy

Advanced Science, EarlyView.
Leveraging 3D bioprinting, this study establishes patient‐derived in vitro models of intrahepatic cholangiocarcinoma. These models faithfully recapitulate the histopathology, molecular profiles, and genomic characteristics of the original patient tumors.
Yuce Lu, Liwei Du, Minghao Sun, Kai Zhang, Mingchang Pang, Shangze Jiang, Jiaxun Dong, Xiyue Liu, Bao Jin, Fu Xu, Hang Sun, Jiangang Zhang, Huiyu Yang, Xiaobo Yang, Xin Lu, Yiyao Xu, Haitao Zhao, Shunda Du, Xinting Sang, Yongchang Zheng, Lei Zhang, Xueshuai Wan, Huayu Yang, Yilei Mao   +23 more
wiley   +1 more source

Regrowth resistance: low-level platinum resistance mediated by rapid recovery from platinum-induced cell-cycle arrest [PDF]

, 2009
The H69CIS200 and H69OX400 cell lines are novel models of low-level platinum drug resistance developed from H69 human small cell lung cancer cells with eight 4-day treatments of 200 ng/ml cisplatin or 400 ng/ml oxaliplatin respectively. A recovery period
Davey, Ross, Stordal, Britta
core   +2 more sources

Combination of Ethoxybenzyl‐Diethylenetriamine Pentaacetic Acid‐Enhanced Magnetic Resonance Imaging and a Serum Biomarker Is Useful in the Diagnosis of Hepatic Sinusoidal Disorder After Chemotherapy Treatment

Annals of Gastroenterological Surgery, EarlyView.
ROC analyses of APRI score, EOB‐MRI, and a combination of EOB‐MRI and APRI score for blue liver. ABSTRACT Aim Sinusoidal obstruction syndrome (SOS), also known as “blue liver (BL),” is a common hepatic injury following oxaliplatin‐based chemotherapy in patients with colorectal liver metastases (CRLM).
Tomonari Shimagaki, Keishi Sugimachi, Takahiro Tomino, Takeshi Kurihara, Emi Onishi, Yutaro Shimomura, Kenji Shinozaki, Masaru Morita   +7 more
wiley   +1 more source

Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta-analysis : Oxaliplatin in neoadjuvant treatment for rectal cancer [PDF]

, 2017
. Background: To evaluate the treatment tolerance and clinical outcomes in patients aged 70 years and older with locally advanced oropharyngeal cancer treated by definitive intensity-modulated radiation therapy (IMRT).
Benevento, Ilaria, Bulzonetti, Nadia, Caiazzo, Rossella, DE FELICE, Francesca, Magnante, ANNA LISA, Musio, Daniela, Tombolini, Vincenzo   +6 more
core   +1 more source

Conversion Therapy for cT4b and M1 Esophageal Squamous Cell Carcinoma: A Comprehensive Systematic Review

Annals of Gastroenterological Surgery, EarlyView.
We systematically reviewed conversion therapy for esophageal squamous cell carcinoma and propose a response‐based treatment strategy for cT4b and M1 disease. For cT4b, we emphasize definitive chemoradiotherapy with timed re‐evaluation and selective salvage or chemoselection to surgery; for M1, conversion is reserved for limited‐burden responders with ...
Eisuke Booka, Hiroya Takeuchi
wiley   +1 more source

ERCC1 expression and RAD51B activity correlate with cell cycle response to platinum drug treatment not DNA repair [PDF]

, 2008
Background: The H69CIS200 and H69OX400 cell lines are novel models of low-level platinum-drug resistance. Resistance was not associated with increased cellular glutathione or decreased accumulation of platinum, rather the resistant cell lines have a cell
A Husain, A Sancar, B Stordal, BK Stordal, Britta Stordal, C Richardson, CH Hensel, DW Melton, E Raderschall, ER McDonald III, ES Child, F Nunez, FM Wachters, G Bepler, H Lincet, HD Preisler, IY Chang, JC Harrison, JJ Yu, JS Russell, K Rothkamm, KA Olaussen, KM Darcy, L Poulain, LF Qin, LF Qin, M Dabholkar, M Takata, M Takata, PA Havre, PA Havre, R Altaha, R Napieralski, R Rosell, RG Sargent, RG Syljuasen, Ross Davey, RVN Lord, S Henness, S Rozen, SG Chaney, T Hata, TT Paull, Y Yonetani   +43 more
core   +2 more sources

Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)

Annals of Oncology, 2018
Background Nivolumab is approved as an option for third- or later-line treatment of advanced gastric/gastroesophageal junction (G/GEJ) cancer in several countries after ATTRACTION-2.
N. Boku, M. Ryu, Ken Kato, H. Chung, K. Minashi, K. Lee, H. Cho, W. Kang, Y. Komatsu, M. Tsuda, K. Yamaguchi, H. Hara, S. Fumita, M. Azuma, L.-T. Chen, L.-T. Chen, Yoon-Koo Kang   +16 more
semanticscholar   +1 more source

Impact of Combined Resection of the Pancreas on Long‐Term Survival in Gastric Cancer

Annals of Gastroenterological Surgery, EarlyView.
Short‐term and long‐term results of patients underwent conbined pancreatectomy was investigated in 64 patients with gastric cancer. R1 resection and postoperative intraabdominal infectious complications were identified as independent prognostic factors.
Taku Hattori, Masanori Terashima, Yusuke Koseki, Kenichiro Furukawa, Keiichi Fujiya, Yutaka Tanizawa, Katsuhisa Ohgi, Teiichi Sugiura, Etsuro Bando   +8 more
wiley   +1 more source